Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced the grant of 45,000 stock options to a new employee, effective October 31, 2022. These options, with an exercise price of $1.06 per share, vest over four years. 25% will vest on the one-year anniversary of the vesting commencement date, with monthly vesting for the remaining shares. This grant is in compliance with Nasdaq Listing Rule 5635(c)(4) and is part of the company's 2019 Equity Incentive Plan. Bellicum focuses on developing controllable cell therapies, particularly CAR-T cell therapies to enhance efficacy.

Positive

• Equity inducement grants signal potential growth through talent acquisition.
• Stock options priced at $1.06 per share may align employee interests with shareholder value as they vest over four years.

Negative

• None.

HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 31, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $1.06 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. The stock options are subject to the terms and conditions of the Company's 2019 Equity Incentive Plan and a stock option agreement covering the grant.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T^® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.

Source: Bellicum Pharmaceuticals

Investors:
Robert H. Uhl
Managing Director
Westwicke IR
858-356-5932
Robert.uhl@westwicke.com 

FAQ

What is the purpose of the stock options granted by Bellicum Pharmaceuticals on October 31, 2022?

The stock options were granted as inducements for a new employee, aimed at aligning their interests with company performance.

What is the vesting schedule for the 45,000 stock options granted by Bellicum Pharmaceuticals?

The options vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly thereafter.

What is the exercise price of the stock options granted to the new employee at Bellicum Pharmaceuticals?

The exercise price is set at $1.06 per share.

Which Nasdaq rule governs the stock option grants made by Bellicum Pharmaceuticals?

The grants comply with Nasdaq Listing Rule 5635(c)(4).

What type of therapies is Bellicum Pharmaceuticals developing?

Bellicum is focused on developing controllable cellular immunotherapies, particularly CAR-T cell therapies.